Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 2, 2015, Pages 139-146

  Zandvliet, Anthe ^a   Glasgow, Shirley ^a   Horowitz, Ann ^a   Montgomery, Diana ^a   Marjason, Joanne ^b   Mehta, Anish ^a   Xu, Christine ^a   Van Vugt, Marianne ^a   Khalilieh, Sauzanne ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Q Pharm Pty Ltd   (Australia)

Author keywords

Chinese subjects; Interleukin 23p19; Japanese subjects; Monoclonal antibody; Psoriasis

Indexed keywords

MONOCLONAL ANTIBODY; TILDRAKIZUMAB; INTERLEUKIN 23;

ADULT; APPENDICITIS; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHINESE; COHORT ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; HEADACHE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; JAPANESE (PEOPLE); MALE; MIDDLE AGED; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE; SUICIDAL IDEATION; UPPER RESPIRATORY TRACT INFECTION; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE RESPONSE; IMMUNOLOGY; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INTERLEUKIN-23; MALE; YOUNG ADULT;

EID: 84961288224     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202176     Document Type: Article

References (15)

1. Schön M P, Boehncke WH. Psoriasis. N Engl J Med. 2005; 352: 1899-1912. CrossRef PubMed
2. Raychaudhuri S P, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001; 15: 16-17. CrossRef PubMed
3. Armstrong A W, Harskamp C T, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012; 2: e54. CrossRef PubMed
4. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995; 1: 442-447. CrossRef PubMed
5. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008; 371: 1675-1684. CrossRef PubMed
6. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005; 45: 792-801. CrossRef PubMed
7. Zhou H, Tsukamoto Y, Davis HM. Should clinical pharmacokinetic bridging studies between Caucasian and Asian populations be required for approval of monoclonal antibodies? J Clin Pharmacol. 2012; 52: 1273-1276. CrossRef PubMed
8. Wang J, Thornton JC, Russell M, Burastero S, Heymsfield S, Pierson RN Jr. Asians have lower body mass index (BMI) but higher percent body fat than do whites: comparisons of anthropomet-ric measurements. Am J Clin Nutr. 1994; 60: 23-28. PubMed
9. Ling J, Lyn S, Xu Z, Achira M, Bouman-Thio E, Shishido A, Ford J, Shankar G, Wagner C, Kim K T, Davis HM, Zhou H. Lack of racial differences in the pharmacokinetics of subcutaneous golim-umab in healthy Japanese and Caucasian male subjects. J Clin Pharmacol. 2010; 50: 792-802. CrossRef PubMed
10. Zhu Y W, Mendelsohn A, Pendley C, Davis HM, Zhou H. Population pharmacokinetics of ustekinu-mab in patients with active psoriatic arthritis. Int J Clin Pharmacol Ther. 2010; 48: 830-846. CrossRef PubMed
11. Zhou H, Mascelli MA. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol. 2011; 51: 359-372. CrossRef PubMed
12. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res. 2006; 23: 1275-1284. Cross-Ref PubMed
13. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, Cohen SB, Rahman MU, Baker D, Mascelli MA, Davis HM, Everitt DE. Pharma-cokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007; 47: 383-396. CrossRef PubMed
14. Frey N, Grange S, Woodworth T. Population phar-macokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010; 50: 754-766. CrossRef PubMed
15. Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, Davis HM, Zhou H. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (siru-kumab) in healthy subjects in a frst-in-human study. Br J Clin Pharmacol. 2011; 72: 270-281. CrossRef PubMed